Filing Flows › Health Care › Acadia Pharmaceuticals (ACAD)
Acadia Pharmaceuticals (ACAD) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Acadia Pharmaceuticals (ACAD) Q3 2026 earnings results →
Q3 2026 Revenue up 23% year over year to $342M · 16¢ of every $1 of revenue kept as net profit · operating margin 21.0%
Acadia Pharmaceuticals made $342M in Q3 2026 (+23% Y/Y): Nuplazid $202M, Daybue $140M. Operating margin 21.0%, net earnings $53.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $342.3M in Q3 2026, up 23% year over year and up 11% from the previous quarter. Nuplazid was the largest line at 59% of revenue. Daybue added $39.0M year over year (up 39%), 61% of the total change.
Operating profit was $71.7M, a 21.0% margin (up 8.1 points year over year). Of the extra revenue versus Q3 2025, 56% reached operating profit, above the 13% margin then. Total costs grew 11% against revenue growth of 23%. The fastest-growing cost line was Cost of revenue (+62%). Net earnings were $53.5M, down 25% year over year. The effective tax rate was 33.5%.
Operating cash flow was $11.5M (down 85% year over year), 21% of net earnings. Non-cash charges added back $3.7M of depreciation and amortization and $17.5M of share-based compensation. Working capital and other items used $63.1M. Capital expenditures of $1.2M left free cash flow of $10.3M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $342M | +23% | 21.0% | $53.5M | $11.5M |
| Q2 2026 | 10-Q | Aug 5, 2026 | $308M | +16% | 12.3% | $31.5M | $101M |
| Q1 2026 | 10-Q | May 7, 2026 | $268M | +10% | -1.7% | $3.6M | $34.0M |
| Q4 2025 | 10-K | Feb 26, 2026 | $284M | +9% | 6.1% | $274M | −$48.7M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $279M | +11% | 12.8% | $71.8M | $74.3M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $265M | +9% | 12.2% | $26.7M | $64.0M |
| Q1 2025 | 10-Q | May 8, 2025 | $244M | +19% | 7.9% | $19.0M | $20.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Acadia Pharmaceuticals
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X .
In its own words, from its 8-K, filed Aug 4, 2026.
Acadia Pharmaceuticals against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +23% against the peers' median +10%. Operating margin: 21.0% against the peers' median 21.0%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ACAD Acadia Pharmaceuticals | Q3 2026 | $342M | +23% | 21.0% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Acadia Pharmaceuticals 10-Q on SEC EDGAR · CIK 1070494 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns ACAD and who is buying
More on ACAD
- How Acadia Pharmaceuticals makes money: revenue by segment
- Acadia Pharmaceuticals next earnings date and what analysts expect
- Acadia Pharmaceuticals stock forecast, price target and fair value
- Who owns Acadia Pharmaceuticals stock: holders, funds and Congress trades
- Acadia Pharmaceuticals guidance and outlook
- Is Acadia Pharmaceuticals a takeover target? LBO and rumors
- Acadia Pharmaceuticals recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Acadia Pharmaceuticals guidance history: guided vs reported
- Acadia Pharmaceuticals operating margin by quarter
- Acadia Pharmaceuticals net income by quarter
- Acadia Pharmaceuticals free cash flow by quarter
- Acadia Pharmaceuticals R&D spending by quarter
- Acadia Pharmaceuticals capital expenditures by quarter
Compare ACAD with
- Acadia Pharmaceuticals vs PTC Therapeutics (ACAD vs PTCT)
- Acadia Pharmaceuticals vs Indivior Pharmaceuticals (ACAD vs INDV)
- Acadia Pharmaceuticals vs BridgeBio Pharma (ACAD vs BBIO)
- Acadia Pharmaceuticals vs Corcept Therapeutics (ACAD vs CORT)
- Acadia Pharmaceuticals vs Prestige Consumer Healthcare (ACAD vs PBH)